NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market. NBY’s Aganocide compounds are patented, synthetic molecules with a spectrum of activity against bacteria, viruses and fungi. The company’s focus is on three therapeutic markets, which includes Dermatology, Ophthalmology and Urology. NBY is also developing NeutroPhase, an FDA 510(k)-cleared product for advanced wound care. For more information, visit the company’s Web site: http://www.novabaypharma.com

Let us hear your thoughts below: